MX2022004501A - Clasificacion de microambientes tumorales. - Google Patents
Clasificacion de microambientes tumorales.Info
- Publication number
- MX2022004501A MX2022004501A MX2022004501A MX2022004501A MX2022004501A MX 2022004501 A MX2022004501 A MX 2022004501A MX 2022004501 A MX2022004501 A MX 2022004501A MX 2022004501 A MX2022004501 A MX 2022004501A MX 2022004501 A MX2022004501 A MX 2022004501A
- Authority
- MX
- Mexico
- Prior art keywords
- population
- tme
- cancer
- subject
- classifiers
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 201000011510 cancer Diseases 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000010801 machine learning Methods 0.000 abstract 1
- 238000007637 random forest analysis Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/24—Classification techniques
- G06F18/241—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches
- G06F18/2415—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on parametric or probabilistic models, e.g. based on likelihood ratio or false acceptance rate versus a false rejection rate
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/04—Architecture, e.g. interconnection topology
- G06N3/048—Activation functions
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/08—Learning methods
- G06N3/084—Backpropagation, e.g. using gradient descent
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2545/00—Reactions characterised by their quantitative nature
- C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
- G05B2219/00—Program-control systems
- G05B2219/30—Nc systems
- G05B2219/32—Operator till task planning
- G05B2219/32335—Use of ann, neural network
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Theoretical Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Data Mining & Analysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Artificial Intelligence (AREA)
- Biochemistry (AREA)
- Databases & Information Systems (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Bioethics (AREA)
Abstract
La descripción proporciona clasificadores basados en la población y no basados en la población para categorizar pacientes y cánceres. Los clasificadores basados en la población descritos integran firmas, es decir, puntuaciones globales relacionadas con la expresión de genes en paneles de genes particulares. Los clasificadores no basados en la población se generan utilizando técnicas de aprendizaje automático (por ejemplo, regresión, bosques aleatorios o ANN). Cada tipo de clasificador estratifica a los pacientes y los cánceres según los microambientes tumorales (TME) como positivos a biomarcador o negativos a biomarcador, y las decisiones de tratamiento se guían por la presencia/ausencia de un TME particular. También se proporcionan métodos para tratar a un sujeto, por ejemplo, un sujeto humano, afectado por cáncer que comprende administrar una terapia particular dependiendo de la clasificación del TME del cáncer según los clasificadores divulgados. También se proporcionan tratamientos personalizados que pueden ser administrados a un sujeto que tiene cáncer clasificado en un TME particular, y a paneles de genes que se pueden usar para identificar a un sujeto humano afectado por un cáncer adecuado para tratamiento con un agente terapéutico particular.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962932307P | 2019-11-07 | 2019-11-07 | |
US202063008367P | 2020-04-10 | 2020-04-10 | |
US202063060471P | 2020-08-03 | 2020-08-03 | |
US202063070131P | 2020-08-25 | 2020-08-25 | |
PCT/US2020/058956 WO2021092071A1 (en) | 2019-11-07 | 2020-11-04 | Classification of tumor microenvironments |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022004501A true MX2022004501A (es) | 2022-05-06 |
Family
ID=73835691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022004501A MX2022004501A (es) | 2019-11-07 | 2020-11-04 | Clasificacion de microambientes tumorales. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210174908A1 (es) |
EP (1) | EP4055609A1 (es) |
JP (1) | JP2023500054A (es) |
KR (1) | KR20220094193A (es) |
CN (1) | CN114556480A (es) |
AU (1) | AU2020378280A1 (es) |
CA (1) | CA3151629A1 (es) |
IL (1) | IL291748A (es) |
MX (1) | MX2022004501A (es) |
TW (1) | TW202132573A (es) |
WO (1) | WO2021092071A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3350183A1 (en) | 2015-09-14 | 2018-07-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
SG10201911541YA (en) | 2017-06-13 | 2020-02-27 | Bostongene Corp | Systems and methods for identifying cancer treatments from normalized biomarker scores |
WO2022266434A1 (en) * | 2021-06-18 | 2022-12-22 | Memorial Sloan-Kettering Cancer Center | Methods for predicting immune checkpoint blockade efficacy across multiple cancer types |
CN113838532B (zh) * | 2021-07-26 | 2022-11-18 | 南通大学 | 基于双重自适应邻域半径的多粒度乳腺癌基因分类方法 |
CN113764032B (zh) * | 2021-10-21 | 2022-02-25 | 北京安智因生物技术有限公司 | 一种荧光定量pcr平台基因智能识别和报告自动化系统 |
TWI816296B (zh) * | 2022-02-08 | 2023-09-21 | 國立成功大學醫學院附設醫院 | 癌症預後的預測方法及其系統 |
WO2023225609A2 (en) * | 2022-05-19 | 2023-11-23 | The University Of Chicago | Methods and systems for molecular subtyping of cancer metastases |
WO2024019471A1 (ko) * | 2022-07-18 | 2024-01-25 | 아주대학교산학협력단 | 지수함수를 이용한 생존곡선 생성 시스템 및 그 방법 |
WO2024035653A1 (en) * | 2022-08-06 | 2024-02-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Predictive biomarker in avastin in colon cancer |
CN117743957B (zh) * | 2024-02-06 | 2024-05-07 | 北京大学第三医院(北京大学第三临床医学院) | 一种基于机器学习的Th2A细胞的数据分选方法及相关设备 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
JP4480715B2 (ja) | 2003-01-29 | 2010-06-16 | 454 コーポレーション | 二重末端シーケンシング |
CA2557841A1 (en) | 2004-02-27 | 2005-09-09 | President And Fellows Of Harvard College | Polony fluorescent in situ sequencing beads |
TWI287041B (en) | 2005-04-27 | 2007-09-21 | Jung-Tang Huang | An ultra-rapid DNA sequencing method with nano-transistors array based devices |
ES2427646T5 (es) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
US20060275779A1 (en) | 2005-06-03 | 2006-12-07 | Zhiyong Li | Method and apparatus for molecular analysis using nanowires |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
US20070194225A1 (en) | 2005-10-07 | 2007-08-23 | Zorn Miguel D | Coherent electron junction scanning probe interference microscope, nanomanipulator and spectrometer with assembler and DNA sequencing applications |
EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
RS53072B (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1 |
BRPI0820298A8 (pt) | 2007-11-09 | 2018-05-08 | Affitech Res As | composições e métodos de anticorpos anti-vegf |
HUE034832T2 (hu) | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
ES2632145T3 (es) | 2010-12-01 | 2017-09-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Modo de predicción del desenlace de un cáncer analizando la expresión de miARN |
US20140018255A1 (en) | 2011-01-11 | 2014-01-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for predicting the outcome of a cancer in a patient by analysing gene expression |
EP3485903B1 (en) | 2011-09-23 | 2022-11-16 | Mereo BioPharma 5, Inc. | Vegf/dll4 binding agents and uses thereof |
EP2805165B1 (en) | 2012-01-20 | 2018-03-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the survival time of a patient suffering from a solid cancer based on density of b cells |
US20150004253A1 (en) | 2012-01-20 | 2015-01-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method for the prognosis of survival time of a patient suffering from a solid cancer |
JP6449765B2 (ja) | 2012-06-14 | 2019-01-09 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 腫瘍組織における免疫細胞を定量するための方法及びその応用 |
PL2872646T3 (pl) | 2012-07-12 | 2018-03-30 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów |
WO2014022594A1 (en) * | 2012-07-31 | 2014-02-06 | Daniel Mercola | Stroma biomarkers for prostate cancer prognosis |
PL2880180T3 (pl) | 2012-08-06 | 2019-04-30 | Assist Publique Hopitaux De Paris | Sposoby i zestawy do badań przesiewowych pacjentów z nowotworem |
RU2648154C2 (ru) * | 2013-07-09 | 2018-03-22 | Аблбио | Новые белки, специфично связывающиеся с двумя мишенями -dll4 и vegf-, и их применение |
JP2016530505A (ja) | 2013-07-15 | 2016-09-29 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 固形癌を患う患者の生存期間の予後判定のための方法 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
SG11201700207WA (en) | 2014-07-11 | 2017-02-27 | Genentech Inc | Anti-pd-l1 antibodies and diagnostic uses thereof |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
CA3058481A1 (en) * | 2017-04-04 | 2018-10-11 | Lung Cancer Proteomics, Llc | Plasma based protein profiling for early stage lung cancer prognosis |
WO2018232142A1 (en) * | 2017-06-14 | 2018-12-20 | Icahn School Of Medicine At Mount Sinai | Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy |
US10636512B2 (en) * | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
-
2020
- 2020-11-04 AU AU2020378280A patent/AU2020378280A1/en active Pending
- 2020-11-04 IL IL291748A patent/IL291748A/en unknown
- 2020-11-04 EP EP20824715.5A patent/EP4055609A1/en active Pending
- 2020-11-04 CN CN202080072728.9A patent/CN114556480A/zh active Pending
- 2020-11-04 CA CA3151629A patent/CA3151629A1/en active Pending
- 2020-11-04 WO PCT/US2020/058956 patent/WO2021092071A1/en unknown
- 2020-11-04 US US17/089,234 patent/US20210174908A1/en active Pending
- 2020-11-04 JP JP2022522801A patent/JP2023500054A/ja active Pending
- 2020-11-04 KR KR1020227012751A patent/KR20220094193A/ko unknown
- 2020-11-04 TW TW109138505A patent/TW202132573A/zh unknown
- 2020-11-04 MX MX2022004501A patent/MX2022004501A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20210174908A1 (en) | 2021-06-10 |
KR20220094193A (ko) | 2022-07-05 |
WO2021092071A1 (en) | 2021-05-14 |
TW202132573A (zh) | 2021-09-01 |
CA3151629A1 (en) | 2021-05-14 |
CN114556480A (zh) | 2022-05-27 |
EP4055609A1 (en) | 2022-09-14 |
AU2020378280A1 (en) | 2022-04-07 |
IL291748A (en) | 2022-06-01 |
JP2023500054A (ja) | 2023-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022004501A (es) | Clasificacion de microambientes tumorales. | |
Nelson et al. | Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions | |
Dawe | Ultraviolet A1 phototherapy | |
Isserles et al. | Cognitive–emotional reactivation during deep transcranial magnetic stimulation over the prefrontal cortex of depressive patients affects antidepressant outcome | |
Li et al. | Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA–N2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy | |
CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
MX2021008605A (es) | Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado. | |
BR112021008549A2 (pt) | Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor | |
Falchi et al. | Subcutaneous (sc) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): first results of a multicenter phase 2 study | |
US20220323450A1 (en) | Methods and compositions for treating neuroblastoma in a juvenile mammalian body | |
Kulchitsky et al. | Prospects of chemotherapy side effects minimization | |
CN107789625A (zh) | 一种braf抑制剂的增敏方法 | |
Mei‐Yen Yong et al. | Targeted and localized phototherapy for atopic dermatitis and psoriasis: An eight‐year experience in a tertiary dermatological centre in Singapore. | |
Inzagi et al. | Negative Impact of Gene Therapy on Melanoma Disease | |
Li et al. | Cutaneous reactions after COVID‐19 vaccination: A single‐center retrospective study in China with 61 cases. | |
Schwartz et al. | Age-Adapted Chemotherapy for Adults> 40 Years Old with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: Single Center Outcomes | |
Zhang et al. | Clinical Efficacy on Severe Acute Radiation Dermatitis Treated by Topical Compound Danxiong Granules in Patients Receiving Radiation: A Prospective Randomized Trial | |
Xu | Stem cell transplantation therapy for acute myeloid leukemia | |
SIVARUBINI | THE LEVEL OF KNOWLEDGE, ATTITUDE AND PRACTICE TOWARDS SMOKING RELATED ORAL CANCER OF UNDERGRADUATE STUDENTS IN FACULTY OF DENTISTRY, UNIVERSITY OF GADJAH MADA | |
Fuerst | CARs Are the Ride of the Future for Curing DLBCL | |
Isiah et al. | Voice Related Quality of Life (qol) in Volumetric Modulated Arc Therapy (vmat) for Non-laryngeal Head and Neck Malignancies | |
Lugin | Engineered Adeno-Associated Viruses for Multi-Modal, Targeted, and Versatile Therapies | |
Alalao et al. | MP26-13 COMPARATIVE EFFECTIVENESS OF CHEMORADIATION VERSUS CHEMOTHERAPY AND RADICAL CYSTECTOMY FOR CLINICALLY NODE-POSITIVE (CN+) BLADDER CANCER | |
Haddad et al. | Side effects and disease-free survival with capecitabine compared to 5FU for concurrent radiochemotherapy of rectal cancer: a 5-year review | |
Mucha-Małecka et al. | EP-1105: Impact of waiting time for treatment initation on glotic T1N0M0 cancer radiotherapy results |